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What you need to know
• Quality evidence to say whether over-the-counter treatments work for
nasal symptoms of the common cold is limited.
• For adults, consider a trial of decongestants alone, or with antihistamines
or analgesics to alleviate bothersome nasal symptoms.
• Do not prescribe decongestants to children under 12, as evidence of
their effectiveness is limited and associated risks may exist.
The common cold is usually caused by viruses and is mostly
self limiting,1 but it can have a substantial impact on work,
school,2 use of health services, and money spent on medications.
Children have around 6-8 colds per year and adults have 2-4.3 4
Many over-the-counter (OTC) treatments for the common cold
claim to alleviate nasal symptoms, such as congestion,
rhinorrhoea (runny nose), and sneezing. Table 1 lists commonly
used drugs. Evidence for the effectiveness of these treatments
is limited and of low quality, and clear guidance is lacking.5
Long term use of nasal decongestants is known to lead to chronic
nasal congestion.6
What is the evidence of uncertainty?
Search strategy and study selection
We searched the Cochrane Library for systematic reviews that investigate the
effectiveness of treatments for the common cold. If only a protocol or no
Cochrane review was available, we searched PubMed for other systematic
reviews on the topic. If no systematic reviews were found, we searched for
individual randomised controlled trials of commonly used treatments (fig 1,
table 2). We extracted data on the subjective severity and duration of nasal
symptoms (nasal congestion, rhinorrhoea, and sneezing) and adverse events.
We extracted the number of studies and participants, and where available,
used pooled results. If pooled results were not available, we assessed whether
the findings were in favour of the active treatment.
Adults
We found Cochrane reviews on treatments such as
decongestants, antihistamines, analgesics, intranasal
corticosteroids, herbal remedies, and vitamins and minerals
(zinc) in adults with common cold. Commonly reported primary
outcomes in the included studies are nasal resistance measures
or outcomes such as clinical cure or composite symptom scores.
Only a few studies included in these reviews report on
bothersome nasal symptoms, such as congestion, rhinorrhoea,
and sneezing. In summary, low quality evidence suggests that
decongestants (either in monotherapy or in combination with
antihistamines and/or analgesics) have a small effect on nasal
symptoms (fig 1). Harms include an increased risk of insomnia,
drowsiness, headache, or gastrointestinal upset (fig 1, table 2).7 11
Long term use can lead to chronic nasal congestion. However,
the recommended safe treatment duration for decongestants
varies and seems to be based on expert opinion.
A Cochrane review8 (four randomised controlled trials, 1466
participants) shows that sedating antihistamines are associated
with relief of rhinorrhoea and sneezing compared with placebo,
but not nasal congestion (two randomised controlled trials, 375
participants). Sedation was commonly reported, but there were
no differences between groups (6 randomised controlled trials,
2265 participants). Studies with non-sedating antihistamines
show an unclear effect on congestion (one randomised controlled
trial, 53 participants), and no effect on rhinorrhoea (three
randomised controlled trials, 838 participants), or sneezing (four
randomised controlled trials, 456 participants) and no increased
risk of adverse events compared with placebo.8
A Cochrane meta-analysis showed no effect of antibiotics on
nasal symptoms, but the risk of adverse events was increased.15
Evidence does not exist for the effectiveness of antivirals, and
intranasal corticosteroids for nasal symptoms in the common
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cold, and their use is not recommended.12 32
Acetaminophen/paracetamol and NSAIDs are sometimes
prescribed for pain relief in common cold, but they do not appear
to improve nasal congestion or rhinorrhoea.9 10 Low quality
evidence suggests intranasal ipratropium bromide reduces
rhinorrhoea compared with placebo, but not nasal congestion.
Nosebleeds, nasal dryness, and dry mouth are side effects.13
Nasal symptoms are not reported in trials investigating the effect
of echinacea,17 vitamin C,16 zinc lozenges,24-26 and heated
humidified air or steam.21 Echinacea does not seem to improve
overall symptoms.17 Zinc lozenges have been shown to reduce
the duration but not severity of cold symptoms,24-26 but the
optimal composition and dosage of lozenges has not been
established. No evidence exists for the use of heated humidified
air or steam in the common cold.21 A Cochrane review concludes
that saline irrigations are not likely to be effective in adults.20
We did not find trials studying the effect on common cold
symptoms for the following treatments: probiotics,27-29 garlic,18
Chinese medicinal herbs,30 vapour rub,22 eucalyptus oil, honey,31
ginseng,23 and increased fluid intake.33
Children
Trials are lacking for children under 12, who carry the highest
burden of common colds. A Cochrane review found low quality
evidence that saline irrigations or drops may be effective and
safe in young children.20 A small number of trials report
contradictory results for decongestants and antihistamines on
nasal symptoms and safety in children.7 8 11 Some products that
contain decongestant may improve nasal symptoms in children,
but their safety, especially in young children, is unclear. We did
not find evidence to support the use of other common treatments
and home remedies in children (such as heated humidified air
or steam, analgesics, echinacea, probiotics, herbs, or vitamins).
Decongestants, antihistamines, and
analgesics in monotherapy
A Cochrane review7 (2 randomised controlled trials, 94
participants) comparing oral or intranasal decongestants with
placebo found that 3-4 doses per day (over 5 days and up to 10
days) was associated with reduced severity of nasal congestion.
Short term adverse events were no different between
decongestants and placebo (7 randomised controlled trials, 1195
participants). No trials compared oral with intranasal routes.
A Cochrane review8 (4 randomised controlled trials, 1466
participants) shows that sedating antihistamines are associated
with relief of rhinorrhoea and sneezing compared with placebo,
but not nasal congestion (2 randomised controlled trials, 375
participants). Sedation was commonly reported, but there were
no differences between groups (6 randomised controlled trials,
2265 participants). Studies with non-sedating antihistamines
show an unclear effect on congestion (1 randomised controlled
trial, 53 participants), and no effect on rhinorrhoea (3
randomised controlled trials, 838 participants), or sneezing (4
randomised controlled trials, 456 participants) and no increased
risk of adverse events compared with placebo.8
In a Cochrane review9 (4 randomised controlled trials, 758
participants), investigating the effect of
acetaminophen/paracetamol compared with placebo on pain
and common cold symptoms, only one trial (n=60) reports
specific nasal symptoms, noting an unclear effect on severity
of symptoms and possible increase of nasal congestion in the
acetaminophen group. Adverse events, such as sweating and
gastrointestinal upset, were more common with high dose
paracetamol (1000 mg) in another trial (n=392). A pooled
analysis of 3 trials (n=199) showed no effect of NSAIDs on
nasal congestion or rhinorrhoea compared with placebo,
although sneezing was reduced (2 randomised controlled trials,
n=159).16 Adverse events, such as rash, oedema and
gastro-intestinal complaints, were not different between groups
(2 randomised controlled trials, n=220).
Combinations of decongestants,
antihistamines, and analgesics
A Cochrane review11 (27 randomised controlled trials, 5117
participants) evaluated the effect of different combinations of
decongestants, antihistamines, and analgesics in the common
cold.
Oral antihistamine decongestant combinations11 and analgesic
decongestant combinations may improve congestion and
sneezing, but data could not be pooled because of heterogeneity.
Patients taking combinations reported more adverse effects such
as sedation, insomnia, and headache.11
Of three trials studying oral antihistamine-analgesic
combinations, two (341 participants) showed no improvement
of nasal congestion compared with placebo or acetaminophen.
In one trial (150 participants) the combination was associated
with less sneezing. Adverse events (nasal irritation, dry mouth,
gastrointestinal upset) occurred in both groups (3 randomised
controlled trials, 1508 participants).11
Oral antihistamine analgesic decongestant combinations11 were
consistently associated with reduced nasal congestion and
rhinorrhoea compared with placebo (3 randomised controlled
trials, 595 participants). It is unclear if adverse events were
different between groups.
Ipratropium bromide
Low quality evidence finds that intranasal ipratropium bromide
reduces rhinorrhoea compared with placebo, but not nasal
congestion, however there is an increased risk of nosebleeds,
nasal dryness, and dry mouth.13 A trial with 786 participants
reported that decongestant ipratropium bromide combination
improved both nasal congestion and rhinorrhoea compared with
placebo, with similar adverse events.14
Antibiotics
Antibiotics are not indicated for viral infections such as the
common cold. A Cochrane meta-analysis15 (6 randomised
controlled trials, 1047 participants) showed that antibiotics did
not reduce duration of purulent rhinitis (4 randomised controlled
trials, 723 participants) or clear rhinitis (2 randomised controlled
trials, 227 participants), but the risk of adverse events was
increased (4 randomised controlled trials, 1267 participants).
Effect on congestion was not reported and there was an unclear
risk of bias overall.
Antivirals
A Cochrane review32 concludes that none of the licensed
antivirals were effective in reducing symptoms, and adverse
events make them unacceptable for use in the common cold.
This review was withdrawn in 2004 as unpublished data from
the original review were not accessible.
Outcomes in children
Few trials investigate the effect of common cold treatments in
children, showing only small effects (fig 1, table 2). In young
children (1.5-60 months) sedating antihistamines were associated
with shorter duration of rhinorrhoea,8 and non-sedating
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antihistamines with shorter duration of overall symptoms, but
nasal symptoms were not reported.8 Adverse events were either
not reported (non-sedating) or not different (sedating).8 The
Cochrane review on combination treatments for common cold
reported that a combination of acetaminophen decongestant
antihistamine in children improved nasal congestion on day 5
(although not on day 3) compared with acetaminophen alone.11
An NSAID decongestant combination reduced the duration of
nasal congestion compared with pseudoephedrine or placebo.11
Antihistamine-decongestant combinations did not show
consistent effects on nasal symptoms.11 Saline nasal irrigation
may improve nasal congestion in older children and possibly
reduce rhinorrhoea severity.20 Vapour rub may improve nasal
congestion (not rhinorrhoea), but at an increased risk of adverse
events.22
A trial with echinacea does not report nasal symptoms, but
shows it increases the risk of a rash.17 The trial of ginseng did
not report nasal symptoms,23 nor did studies with honey.5
Furthermore, we did not find any trials studying the effect of
the following treatments in children with common cold:
decongestants in monotherapy,7 NSAIDs10 or paracetamol9 in
monotherapy, intranasal corticosteroids,12 intranasal ipratropium
bromide,13 antivirals,32 eucalyptus oil,22 fluid intake,33 garlic,18
heated humidified air,21 Chinese medicinal herbs,30 Pelargonium
sidoides,19 probiotics,27-29 vitamin C,16 and zinc.25 26
Is ongoing research likely to provide
relevant evidence?
A search of International Clinical Trials Registry Platform using
the terms “common cold” or “respirat*” yielded 17 references
to ongoing trials. These trials use
analgesic-decongestant-antihistamine combinations (n=3), an
intranasal decongestant (n=1), Chinese (n=3) or other herbs
(n=4), herbal steam inhalation (n=1), lactic acid bacteria (n=1),
pelargonium (n=1), guaifenesin (n=1), and antivirals (n=2).
Twelve of these trials include adults (and older children), four
include only children, and one includes participants of all ages.
Most of these studies have reasonable sample sizes but few
report on nasal symptoms. Five trials explicitly mention they
will report on nasal symptoms, and only one of these includes
children. Several traditional Chinese, Thai, and Indian herbal
treatments are also studied, but none of these trials will provide
information about the effect on nasal symptoms. It is unlikely
that these will address the uncertainty. No evidence yet exists
on the effect of guaifenesin, an expectorant used to treat cough,
on nasal symptoms. This study may add to the evidence base.
What should we do in light of the
uncertainty?
The common cold is self limiting and symptoms usually clear
within 7 to 10 days.34 Explain to patients that there are no “magic
bullets” to relieve their symptoms and that very few OTC
treatments are supported by evidence.
For adults with bothersome nasal symptoms, decongestants and
antihistamines in monotherapy or in combination products are
the best choice. However, the effect is small and although the
adverse events are usually mild, some—such as sedation—can
be disturbing. No evidence suggests that a tablet taken orally
or a nasal spray is the more effective. Advise patients to use
nasal decongestants for a maximum of 3 to 7 days.35-38 Patients
often take OTC decongestants before they consult the GP and
commonly for more than just a few days.6 They may not be
aware that prolonged use can lead to chronic nasal congestion
(rhinitis medicamentosa). None of the other commonly used
OTC treatments have been shown to relieve nasal symptoms
and many have not been studied at all. Based on the currently
available evidence, reassurance that symptoms are self limiting
is the best you can offer patients.
The evidence for common cold treatments in children is more
limited. We do not recommend decongestant or formulations
containing antihistamine in children under 6 and advise caution
between 6 and 12 years.35-38 There is no evidence that these
treatments alleviate nasal symptoms and they can cause adverse
effects such as drowsiness or gastrointestinal upset. Serious
harm, such as convulsions, rapid heart rate and death have been
linked to decongestant use in very young children. None of the
other commonly used OTC and home treatments, such as heated
humidified air, eucalyptus oil, or echinacea are supported by
adequate evidence.
Explain that a cold is distressing but should pass in 7-10 days.
If parents are concerned about their child’s comfort, saline nasal
irrigations can be given to alleviate nasal symptoms.
Recommendations for future research
Large, well conducted randomised controlled trials should include
• Population: children, especially young children as they carry the highest
burden of common colds
• Intervention: commonly used treatments such as nasal irrigations, steam
inhalations or vaporizers with humidified air, eucalyptus or other aromatic
oils, or vapour rub
• Comparator: other commonly used treatments or head-to-head
comparisons of active products (such as oral or intranasal
decongestants)
• Outcome: outcomes relevant to patients, eg, subjective nasal congestion
rather than nasal patency, impact on daily life, short- and long term
safety
Education into practice
• How do you discuss treatments for nasal symptoms of the common
cold? With an adult? With the parent of a child?
• How would you explore duration of use for decongestant, and how
would you address this issue?
What patients need to know
Common cold is usually self limiting—symptoms clear in 7 to 10 days. Your
doctor may offer you medications to relieve headache, pain, or nasal
congestion if these are bothersome.
• Adults
o If a blocked or runny nose, or sneezing related to a cold is bothering
you, you can try using nasal decongestants for up to 3 to 7 days
o Beware of unintended effects such as drowsiness, insomnia, or
headache
o Do not take decongestants longer than advised as long term use may
lead to chronic nasal congestion, which is difficult to treat
o Other treatments have either not been effective in clinical trials or have
not been studied at all
• In children under 12
o Saline nasal irrigations or drops can be used safely, but this may not
give the desired relief
o Consult a doctor if symptoms are bothersome. Do not give children
decongestants
o Vapour rub may relieve congestion but can cause skin rashes
o Other treatments, such as steam, humidified air, echinacea, or probiotics,
are either not effective or have not been studied in children.
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Information resources for patients
NHS Choiceshttp://www.nhs.uk/conditions/Cold-common/Pages/
Introduction.aspx
Definition of common cold, symptoms, treatment, complications, children.
Free of charge. No registration needed
Mayo Clinichttp://www.mayoclinic.org/diseases-conditions/common-cold/
home/ovc-20199807#
Overview, symptoms and causes, diagnosis and treatment,
self-management. Free of charge. No registration needed
How patients were involved in the creation of this article
We asked 10 customers seeking OTC treatments for the common cold in a
community pharmacy in Belgium what concerned them most when they had
a cold. This revealed a strong focus on managing nasal symptoms. Based on
this, we decided to focus on the effect of commonly used treatments on
subjective nasal symptoms in common cold. A patient reviewer acknowledged
that while there is no clear cut way to resolve symptoms of nasal congestion,
appropriate treatment options can be discussed for adults and for children.
We have now presented the evidence for common treatments for adults and
children separately and also clarified these in the section on ‘what patients
need to know’.
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Tables
Table 1| Drugs used to treat symptoms in common cold
Decongestant
Ephedrine hydrochloride, pseudoephedrine hydrochloride, phenylephrine hydrochlorideSympathomimetic: oral
Naphazoline nitrate, oxymetazoline hydrochloride, tramazoline hydrochloride, xylometazoline hydrochlorideSympathomimetic: intranasal
Antihistamine
Alimemazine tartrate, chlorphenamine maleate, clemastine, cyproheptadine hydrochloride, dimethindene
maleate,
a
 hydroxyzine hydrochloride, ketotifen, promethazine hydrochloride
Older, “first generation,” sedating
Acrivastine, azelastine hydrochloride,
bbb
 bilastine, cetirizine hydrochloride, desloratadine, fexofenadine
hydrochloride, levocabastine hydrochloride,
bbb
 levocetirizine hydrochloride, loratadine, mizolastine,
olopatadine hydrochloride
bbb
Newer, “second generation,” non-sedating
Acetaminophen/paracetamolAnalgesic
Non-steroidal anti-inflammatory drugs (NSAIDs):
acetylsalicylic acid (aspirin), ibuprofen, naproxen
Beclomethasone diproprionate, budesonide, ciclesonide, fluticasone furoate/propionate, flunisolide,
mometasone furoate, triamcinolone acetonide
Nasal corticosteroids
Ipratropium bromideAntimuscarinic
Sodium chloride 0.9% (saline)Saline nasal irrigation
Availability and OTC status of the products vary by country
* Both oral and intranasal
** Intranasal
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Table 2| Efficacy (subjective nasal symptoms) and harm of common cold treatments in adults and children: overview of the available
evidence from Cochrane reviews and clinical trials
ChildrenAdults
GradeEffectIncluded
studies
GradeEffectIncluded
studies
OutcomeTreatment option
No RCTs
available
Low*Small effect on severity
aaaaaaaaaaaaaaaaaaaabb
:
Pooled effect after 3 hours: SMD 0.49 (95% CI 0.07 to 0.92)
n=94; 2
RCTs
CongestionDecongestants
Cochrane review7
No RCTs
available
Not
reported
Rhinorrhoea
No RCTs
available
Not
reported
Sneezing
No RCTs
available
Low*No increased risk:
Pooled risk: OR 0.98 (95% CI 0.68 to 1.40)
n=1195;
7 RCTs
Adverse
events
ModerateUnclear
effect on
severity
No pooling:
1 RCT no
effect
n=150; 1
RCT
LowNo effect on severity
aaaaaaaaaaaaaaaaaaaabbaaaaaaaaaaaaaaaaaaaabb
:
Pooled effect after day 1: MD −0.07 (95% CI −0.29 to 0.15); scale 0-4
n=375; 2
RCTs
CongestionSedating antihistamines
Cochrane review8
LowUnclear effect on duration:
No pooling: 1 RCT shows no effect
n=27; 1
RCT
ModerateUnclear
effect on
severity
No pooling:
1 RCT no
effect
n=150; 1
RCT
HighSmall effect on severity
aaaaaaaaaaaaaaaaaaaabbaaaaaaaaaaaaaaaaaaaabb
:
Pooled effect after day 1: MD −0.04 (95% CI −0.13 to 0.06); scale 0-4
Pooled effect after day 2: MD −0.18 (95% CI −0.27 to −0.08); scale 0-4
n=1466;
4 RCTs
n=1465;
4 RCTs
Rhinorrhoea
ModerateUnclear
effect on
duration
No pooling:
significant
effect day 7
n=150; 1
RCT
LowUnclear effect on duration
No pooling: 1 RCT no effect
n=27; 1
RCT
Not
reported
HighSmall effect on severity
aaaaaaaaaaaaaaaaaaaabbaaaaaaaaaaaaaaaaaaaabb
:
Pooled effect after day 1: MD −0.07 (95% CI −0.15 to 0.00); scale 0-4
Pooled effect after day 2: MD −0.29 (95% CI −0.38 to −0.21) scale 0-4)
n=1466;
4 RCTs
n=1465;
4 RCTs
Sneezing
LowUnclear effect on duration
No pooling: 1 RCT no effect
n=27; 1
RCT
ModerateUnclear
risk
No pooling:
no
difference
for sedation
n=150; 1
RCT
LowNo increased risk
Pooled OR 1.13 (95% CI 0.80 to 1.59)
n=2265;
6 RCTs
Adverse
events
Not
reported
LowUnclear effect on severity
No pooling: 1 RCT no effect
n=53; 1
RCT
CongestionNon-sedating antihistamines
Cochrane review8
Not
reported
Very lowNo effect on severity
aaaaaaaaaaaaaaaaaaaabbaaaaaaaaaaaaaaaaaaaabb
Pooled effect after day 4: MD −0.08 (95% CI −0.26 to 0.09); scale 0-4
n=383; 3
RCTs
Rhinorrhoea
Not
reported
LowPossibly no effect on severity
No pooling: 4 RCTs no effect
n=456; 4
RCTs
Sneezing
ModerateUnclear
risk
No pooling:
no AE
reported
n=62; 1
RCT
Very lowNo increased risk
Pooled OR 1.21 (95% CI 0.52 to 2.81)
n=215; 3
RCTs
Adverse
events
No RCTs
available
ModerateUnclear effect on severity
No pooling: increased nasal congestion
n=60; 1
RCT
CongestionParacetamol/
Acetaminophen
Cochrane review9
No RCTs
available
Not
reported
Rhinorrhoea
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Table 2 (continued)
ChildrenAdults
GradeEffectIncluded
studies
GradeEffectIncluded
studies
OutcomeTreatment option
No RCTs
available
Not
reported
Sneezing
No RCTs
available
ModerateUnclear risk
No pooling: more minor AE, not clear if differences between groups
1 RCT
(n=392)
Adverse
events
No RCTs
available
Moderate*No effect on severity
aaaaaaaaaaaaaaaaaaaabbaaaaaaaaaaaaaaaaaaaabb
Pooled SMD −0.15 (95% CI −0.43 to 0.13)
n=199; 3
RCTs
CongestionNSAIDs
Cochrane review10
No RCTs
available
Moderate*No effect on
severity
aaaaaaaaaaaaaaaaaaaabbaaaaaaaaaaaaaaaaaaaabbaaaaaaaaaaaaaaaaaaaabb
Pooled SMD 0.03 (95% CI −0.25 to 0.30)
n=199; 3
RCTs
Rhinorrhoea
No RCTs
available
ModerateSmall effect on severity
aaaaaaaaaaaaaaaaaaaabbaaaaaaaaaaaaaaaaaaaabb
Pooled SMD −0.44 (95% CI −0.75 to −0.12)
n=159; 2
RCTs
Sneezing
No RCTs
available
LowNo increased risk
Pooled RR 2.94 (95% CI 0.51 to 17.03)
n=220; 2
RCTs
Adverse
events
Very lowUnclear
effect on
severity
No pooling:
3 RCTs
(n=131) no
n=191; 3
RCTs
Very lowUnclear effect on severity
No pooling: 3 RCTs (n=568) significant effect, 2 RCTs (n=110) no effect
n=678; 5
RCTs
CongestionAntihistamine-decongestant
combination
Cochrane review11
effect, 1
RCT (n=60)
significant
effect
Very lowUnclear
effect on
severity
No pooling:
2 RCTs
(n=113) no
n=173; 3
RCTs
Very lowUnclear effect on severity
No pooling: 2 RCTs (n=369) significant effect, 2 RCT (n=291) no effect
n=660; 4
RCTs
Rhinorrhoea
effect, 1
RCT (n=60)
significant
effect
ModerateUnclear
effect on
severity
No pooling:
Significant
effect
n=60; 1
RCT
LowPossible effect on severity
No pooling: 3 RCTs significant effect
n=574; 3
RCTs
Sneezing
Very lowUnclear
risk
No pooling:
2 RCTs
(n=113; ≤6
years) no
n=231; 4
RCTs
Very lowNo increased
risk
aaaaaaaaaaaaaaaaaaaabbaaaaaaaaaaa aaaaaaaabbaaaaaaaaaaaaaaaaaaaabb
Pooled OR 1.58 (95% CI 0.78 to 3.21)
n=842; 7
RCTs
Adverse
events
increase.
Two RCTs
(n=118; ≥6
years,
unclear if
adults
included)
reported
AE, but
unclear if
different or
which AE
No RCTs
available
Very lowUnclear effect on severity
No pooling: 2 RCTs (n=341) no effect, 1 RCT (n=1167) significant effect
n=1508;
3 RCTs
CongestionAntihistamine-analgesic combination
Cochrane review11
No RCTs
available
Not
reported
Rhinorrhoea
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Table 2 (continued)
ChildrenAdults
GradeEffectIncluded
studies
GradeEffectIncluded
studies
OutcomeTreatment option
No RCTs
available
LowUnclear effect on severity
No pooling: significant effect on day 5
n=150; 1
RCT
Sneezing
No RCTs
available
LowPossibly no increased risk
No pooling: 3 RCTs no difference in AE
n=1508;
3 RCTs
Adverse
events
LowUnclear
effect on
duration
No pooling:
significant
effect
n=65; 1
RCT
Very lowPossible effect on severity
No pooling: 4 RCTs (n=1436) significant effect; 1 RCT (n=191) no effect
n=1627;
5 RCTs
CongestionAnalgesic-decongestant combination
Cochrane review11
Not
reported
LowPossibly no effect on severity
No pooling: 3 RCTs no effect
n=679; 3
RCTs
Rhinorrhoea
Not
reported
LowPossibly no effect on severity
No pooling: 2 RCTs no effect
n=621; 2
RCTs
Sneezing
Not
reported
ModerateIncreased risk
Pooled OR 1.71 (95% CI 1.23 to 2.37; NNH 14)
n=1440;
5 RCTs
Adverse
events
ModerateUnclear
effect on
severity
No pooling:
no effect on
day 3
n=201; 1
RCT
LowPossible effect on severity
No pooling: 3 RCTs significant effect
n=595; 3
RCTs
CongestionAntihistamine-analgesic-decongestant
combination
Cochrane review11
ModerateUnclear
effect on
severity
No pooling:
no effect on
day 3
n=201; 1
RCT
LowPossible effect on severity
No pooling: 3 RCTs significant effect
n=595; 3
RCTs
Rhinorrhoea
Not
reported
ModerateUnclear effect on severity
No pooling: no effect
n=70; 1
RCT
Sneezing
ModerateUnclear
risk
No pooling:
no AE
reported
n=201; 1
RCT
LowUnclear risk
No pooling: unclear if differences between groups
n=595; 3
RCTs
Adverse
events
No RCTs
available
Not
reported
CongestionIntranasal corticosteroids
Cochrane review12
No RCTs
available
Not
reported
Rhinorrhoea
No RCTs
available
Not
reported
Sneezing
No RCTs
available
LowUnclear risk
No pooling: no differences
n=200; 1
RCTs
Adverse
events
No RCTs
available
LowPossibly no effect on severity
No pooling: 4 RCTs no significant effect
n=1081;
4 RCTs
CongestionIntranasal ipratropium bromide
Cochrane review13
No RCTs
available
LowPossible effect on severity
No pooling: 4 RCTs significant effect
n=1959;
4 RCTs
Rhinorrhoea
No RCTs
available
ModerateNot
reported
Sneezing
No RCTs
available
Increased risk
Epistaxis: OR 3.21 (95% CI 1.68 to 6.13)
Nasal dryness: OR 2.55 (1.50 to 4.33)
Dry mouth: OR 3.59 (1.38 to 9.38)
Other AE: not significant
No RCTs
available
Adverse
events
No RCTs
available
LowUnclear effect on severity
No pooling: significant effect after 24 hrs
n=786; 1
RCT
CongestionDecongestant - ipratropium bromide
combination
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Table 2 (continued)
ChildrenAdults
GradeEffectIncluded
studies
GradeEffectIncluded
studies
OutcomeTreatment option
No RCTs
available
LowUnclear effect on severity
No pooling: significant effect after 24 hrs
n=786; 1
RCT
RhinorrhoeaSystematic review14
No RCTs
available
Not
reported
Sneezing
No RCTs
available
LowUnclear risk
No pooling: significantly higher incidence of blood-tinged mucus, epistaxis, nasal passage irritation, and nasal dryness
with ipratropium bromide
n=786; 1
RCT
Adverse
events
Not
reported
Not
reported
CongestionAntibiotics
Not
reported
Very lowNo effect on duration/persistence of purulent rhinitis
Pooled RR 0.73 (95% CI 0.47 to 1.13)
n=723; 4
RCTs
RhinorrhoeaCochrane review15
LowNo effect on duration/persistence of clear rhinitis
Pooled RR 0.58 (95% CI 0.23 to 1.48)
n=227; 2
RCTs
Not
reported
No RCTs
available
Sneezing
Very lowNo
increased
risk
Pooled RR
0.91 (95%
CI 0.51 to
1.63)
n=228; 2
RCTs
LowIncreased risk
Pooled RR 2.62 (95% CI 1.32 to 5.18)
n=1267;
4 RCTs
Adverse
events
No RCTs
available
Not
reported
Congestion,
rhinorrhoea
and
sneezing
Vitamin C
Cochrane review16
No RCTs
available
Very lowNo increased risk
aaaaaaaaaaaaaaaaaaaabbb
No pooling: no difference, nature of AE not reported
n=4556;
7 RCTs
Adverse
events
No RCTs
available
No RCTs
available
Congestion,
rhinorrhoea
and
sneezing
Echinacea
Cochrane review17
LowUnclear
risk
No pooling:
unclear if
differences,
but
n=407; 1
RCT
Very lowPossibly no increased risk
No pooling: 1 RCT increased risk, 6 RCTs no difference, AE not reported
n=1108;
7 RCTs
Adverse
events
increased
frequency
of rash
No RCTs
available
Not
reported
Congestion,
rhinorrhoea
and
sneezing
Garlic
Cochrane review18
No RCTs
available
LowUnclear risk
No pooling: Unclear if different
n=146; 1
RCT
Adverse
events
No RCTs
available
LowUnclear effect on severity
No pooling: Significant effect by day 5
n=103; 1
RCT
CongestionPelargonium sidoides extract
Cochrane review19
No RCTs
available
Not
reported
Rhinorrhoea
No RCTs
available
Not
reported
Sneezing
No RCTs
available
LowUnclear risk
No pooling: No difference in AE
n=103; 1
RCT
Adverse
events
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Table 2 (continued)
ChildrenAdults
GradeEffectIncluded
studies
GradeEffectIncluded
studies
OutcomeTreatment option
Very lowUnclear
effect on
severity
No pooling:
2 RCTs
n=540; 3
RCTs
LowPossibly no effect on severity
No pooling: 2 RTCs no effect on day 3
n=205; 2
RCTs
CongestionSaline nasal irrigation
Cochrane review20
(n=470)
significant
effect, 1
RCT (n=74)
no effect on
day 3
Very lowPossible
effect on
severity
No pooling:
2 RCTs
significant
effect
n=470; 2
RCTs
No RCTs
available
Rhinorrhoea
No RCTs
available
No RCTs
available
Sneezing
Very lowUnclear
risk
No pooling:
AE
reported,
unclear if
different
n=475; 2
RCTs
ModerateUnclear risk
No pooling: no difference in AE
n=143; 1
RCT
Adverse
events
No RCTs
available
No RCTs
available
Congestion,
rhinorrhoea,
and
sneezing
Heated humidified air
Cochrane review21
No RCTs
available
Very lowUnclear risk
No pooling: minor AE, unclear if different
n=203; 3
RCTs
Adverse
events
LowUnclear
effect on
severity
No pooling:
significant
effect
n=138; 1
RCT
No RCTs
available
CongestionVapour rub
RCT22
LowUnclear
effect on
severity
No pooling:
no effect
n=138; 1
RCT
No RCTs
available
Rhinorrhoea
No RCTs
available
No RCTs
available
Sneezing
LowUnclear
risk
No pooling:
increased
risk of
burning
n=138; 1
RCT
No RCTs
available
Adverse
events
sensation of
skin, nose
and eyes
Not
reported
No RCTs
available
Congestion,
rhinorrhoea,
and
sneezing
Ginseng
RCT23
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Table 2 (continued)
ChildrenAdults
GradeEffectIncluded
studies
GradeEffectIncluded
studies
OutcomeTreatment option
ModerateUnclear
risk
No pooling:
no AE
n=45; 1
RCT
No RCTs
available
Adverse
events
No RCTs
available
No RCTs
available
Congestion,
rhinorrhoea,
sneezing
and adverse
events
Antiviralsv 20,
zinc,24-26probiotics,27-29Chinese medicinal
herbs,30honey,31 eucalyptus oil,22fluid
intakevi 36
“No effect” indicates that data were pooled and the overall effect estimate was not statistically significant. A “possible effect” is based on a qualitative appreciation of the effects reported in individual trials that could not be pooled. Effect
size was based on what the authors reported and on the Cochrane Handbook (eg, a standardised mean difference of 0.2 to 0.49 represents a small, 0.5 to 0.79 a moderate, and ≥0.8 a large clinical effect). If no pooling was available but
results were consistent, we concluded there was a possible effect or possibly no effect. Quality of evidence was based on the GRADE assessment reported in the review (indicated with *), if no GRADE assessment was available in the
review we assigned a GRADE assessment (see supplementary table); NSAIDs: non-steroidal anti-inflammatory drugs; GI: gastrointestinal; AE: adverse events; CI: confidence interval; OR: odds ratio; MD: mean difference; RR: relative
risk.
iPositive scores represent treatment benefit; 
aaaaaaaaaaaaaaaaaaaabbaaaaaaaaaaaaaaaaaaaabb
negative scores represent treatment benefit
iiiThis meta-analysis included one study that might have included children (n=60), although the age of the participants was not clear
ivIt was not clear from the review which studies recorded adverse events, therefore we were not able to differentiate between adults and children
vThe review on antivirals has been withdrawn, no new updated Cochrane review has been published
viThe review on fluid intake did not identify any relevant trials
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Figure
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Fig. 1Benefit and harm of common cold treatments in adults and children: a summary based on analysis of the evidence
from Cochrane reviews and clinical trial. “No effect” indicates that data were pooled and the overall effect estimate
was not statistically significant. A “possible” effect is based on a qualitative appreciation of the effects reported in
individual trials that could not be pooled. Interpretation of the size of the effect was based on what the authors reported
and on the Cochrane Handbook (eg, a standard mean difference of 0.2 to 0.49 represents a small, 0.5 to 0.79 a
moderate, and ≥0.8 a large clinical effect). If no pooling was available but results were consistent, we concluded there
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was a possible effect or possibly no effect. * The Cochrane review on antivirals has been withdrawn, no new updated
Cochrane review has been published. † The Cochrane review on fluid intake did not identify any relevant trials
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